ImmuCell Stock

ImmuCell EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of ImmuCell (ICCC) as of Aug 6, 2026 is 3.88 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -3.67 % — a change of -205.64% (higher).

EBIT/Assets

3.88 %

YoY

-205.64%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of ImmuCell is 2026 3.88 % . Operating Income to Assets Ratio (EBIT/Assets) of ImmuCell was 2025 -3.67 % . It decreases by -205.64% higher compared to the previous year.
Access this data via the Eulerpool API

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

Operating Income to Assets Ratio (EBIT/Assets) of ImmuCell is 3.88 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of ImmuCell changed from -3.67 % to 3.88 %, representing a -205.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) ImmuCell since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s ImmuCell with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

Profitability — ImmuCell

All Key Metrics — ImmuCell